Azimuth Sleep Solutions announced today that it received FDA emergency use authorization (EUA) for its PortPatch product.

PortPatch, a patent-pending product, is designed to expand air filtration capabilities for patient treatment options and to keep healthcare workers safer in patient care areas in which non-invasive ventilatory treatment devices are in use.

Memphis, Tenn.-based Azimuth Sleep Solutions makes the PortPatch with a hydrophobic, N99-rated filter material to filter out 99% of airborne particulates through exhalation ports, anti-asphyxia valves and carbon dioxide vents on CPAP, BiPAP and other non-invasive ventilation masks, according to a news release.

The company said independent test data for the product showed zero retention of carbon dioxide, while PortPatch also remained in place over vents and ports during tests of low-to-very-high levels of airflow pressures.

PortPatch offers improved safety in CPAP and BiPAP use in all patient care settings, with its universal capabilities available for any design or brand of CPAP mask.

“We are excited to bring this new option to health care providers and patients around the country,” Azimuth Sleep Solutions CEO & co-founder Dr. Kristen Archbold said in the release. “During this global pandemic we are all focused on innovative ways to increase safety for health care workers and expand treatment options for patients.”